IgA Nephropathy

Pregnancies occurring during or after initial C3G presentation were at a greater risk of preeclampsia, prematurity, and renal function decline.

Recent research uncovers how lifestyle and environmental factors influence the incidence of IgAN and membranous nephropathy.

Symptoms of immunoglobulin A nephropathy were reduced substantially during the 1-month follow-up period.

The month in review spotlights renal FDA news and novel research about CKD and social determinants of health in kidney care.

Kraus explains current unmet needs in IgA nephropathy and what sibeprenlimab may offer based on the phase 3 VISIONARY study.

Our Q1 recap for nephrology spotlights regulatory updates, new clinical trial data, and advancements in xenotransplant.

The approval indicates Novartis's atrasentan (Vanrafia) for proteinuria reduction in primary IgA nephropathy.

The March 2025 month in review spotlights a new episode of Crisis Point about CKD for National Kidney Month and renal FDA news.

The FDA accepted an sNDA for pegcetacoplan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

The Biologics License Application submission for sibeprenlimab is supported by results from the phase 2 ENVISION and phase 3 VISIONARY clinical trials.

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial.

Lerma discusses the current treatment landscape for IgA nephropathy and what role APRIL inhibition may play in treating IgAN.

The submission is supported by results from the phase 3 DUPLEX Study and the phase 2 DUET Study in adult and pediatric patients with FSGS.

In part 1 of this episode of Crisis Point, 3 nephrology experts and a patient advocate discuss CKD’s emergence as a public health crisis.

The nephrology month in review spotlights HCPLive’s coverage of renal trial developments, xenotransplant, new AKI guidance, and research about dialysis.

In the final segments of this 4-part episode, the discussion focuses on the use of HCEs in different kidney disease trials.

In part 3 of 4 from this episode, the discussion focuses on potential limitations to HCEs and addressing skepticism around their use in nephrology.

In part 2 of 4 from this episode, the discussion focuses on hierarchical composite endpoints and their use in nephrology trials and research.

In part 1 of 4 from this episode, the discussion focuses on traditional composite endpoints in nephrology trials and the use of HCEs.

The analysis of 2004-2024 Google Trends data revealed varying levels of public interest in IgAN, MD, FSGS, LN, and DN.

The month in review spotlights the top news and research in nephrology from January, including an FDA approval and new IgAN research.

Findings highlight the wide variety of outcomes experienced by patients with IgAN and the limited insights offered by clinical data at diagnosis.

Study findings point to the prognostic value of anti-ETAR and anti-CXCR3 antibodies in IgA nephropathy and lupus nephritis.

Findings show differences in the clinicopathological characteristics and prognosis of patients with IgAN and nephrotic syndrome across renal pathologies.

The study leverages large US-based claims datasets and pathologist input to estimate the annual incidence and total prevalence of IgAN in the US.